Evidence map›Paper›PMID 42769581›Full record

ArticleRSC advances2026

Enhanced

Nuntika Wangpradit, Fonthip Makkliang, Arpa Petchsomrit, Gorawit Yusakul

Abstract read
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nuntika WangpraditInternational College of Dentistry, Walailak University Nakhon Si Thammarat 80160 Thailand.ORCID https://orcid.org/0000-0003-3863-4554
Fonthip MakkliangFunctional Materials and Nanotechnology Center of Excellence, Walailak University Nakhon Si Thammarat 80160 Thailand.ORCID https://orcid.org/0000-0002-5202-2266
Arpa PetchsomritDivision of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Burapha University Bangsaen, Mueang Chonburi 20131 Thailand.ORCID https://orcid.org/0000-0003-3863-9451
Gorawit YusakulDepartment of Pharmaceutical Chemistry and Pharmacognosy, Faculty of Pharmaceutical Sciences, Naresuan University Phitsanulok 65000 Thailand gorawity@nu.ac.th.ORCID https://orcid.org/0000-0002-4575-4936

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Curcumin has considerable therapeutic potential; however, its poor solubility and permeability limit its clinical applications. We evaluated menthol-based hydrophobic deep eutectic solvents (HDES) as oil phases in microemulsions to address these challenges. HDES were formulated by combining l-menthol with acids (lactic, decanoic, dodecanoic, and oleic acids) and incorporating them into microemulsions using surfactant mixtures of Cremophor RH40 (CrRH40) and diethylene glycol monoethyl ether or CrRH40 and Labrasol, with a 3 : 7 oil-to-surfactant ratio. Oleic acid, coconut oil, and medium chain triglyceride were used as the conventional oil phase. Physical properties, curcumin solubility in microemulsion, and their effects on

Identifiers

PMID42769581
PMCPMC13591768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.